Cell reports. Medicine · 2026
Iparomlimab and tuvonralimab in previously treated patients with cervical cancer.
СтатьяМногоцентровое исследованиеКлиническое исследование II фазыНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lou Hanmei, Zhou Yun, Li Dapeng, Zhang Hongping, Zhang Mingjun, Wang Lihua, Cheng Huijun, Liu Zi, Duan Wei, Feng Mei, Zhang Jieqing, Chen Lipai, Wang Danbo, Yu Jinjin, Li Congzhu, Wang Chao, Wang Peizhen, Li Hui, Kang Xiaoyan, Liu Jihong
Аннотация
Iparomlimab and tuvonralimab (QL1706) is a bifunctional antibody containing anti-programmed death-1 IgG4 and anti-cytotoxic T-lymphocyte antigen 4 IgG1. This multi-center single-arm phase 2 trial recruits patients with recurrent or metastatic cervical cancer (r/m CC) who have failed at least first-line platinum-based chemotherapy with or without bevacizumab. QL1706 is administered at a dose of 5.0 mg/kg every 3 weeks via intravenous infusion. The primary endpoint is objective response rate (ORR) per independent review committee (IRC). In a total of 148 patients, the confirmed ORR and disease control rate are 33.3% (95% confidence interval [CI]: 25.8%-41.6%) and 65.3% (95% CI: 57.0%-73.0%) per IRC, respectively. The median progression-free survival is 5.4 months (95% CI: 3.9-6.9). The median overall survival is 17.1 months (95% CI: 14.8 to not evaluable). Treatment-related adverse events occur in 107 (72.3%) patients. No treatment-related death occurs. QL1706 shows promising efficacy and is well tolerated in previously treated patients with r/m CC. The trial is registered at clinicaltrials.gov (NCT05557565).